The future for drug developers is defined by how effectively they adopt innovative pharma R&D strategies and new technologies while navigating industry challenges and complexities.
That’s why the PPD clinical research business of Thermo Fisher Scientific surveyed 150 leaders at biotech and pharmaceutical organizations around the globe to assess trends in drug discovery and development. Respondents shared the therapeutic areas in their pipelines, barriers to bringing drugs to market, innovations that are driving transformation and attitudes toward key topics such as outsourcing, patient recruitment, diversity, decentralized trials and more.
In this webinar, the panel of experts will highlight findings from the pharma R&D report and go beyond the data to explain what they mean for drug developers across the globe. Attendees will hear about the keys to success and prepare to successfully navigate the evolving drug development landscape. In addition, attendees will learn what industry leaders are facing today, and how their outlook on pharmaceutical research and development will influence the industry moving forward.
Join this webinar to get insights into how clinical research professionals are approaching key issues and where the industry is headed.
Speakers
Matt Latey, VP, Head of Development Operations, Biopharma, PPD, part of Thermo Fisher Scientific
Matt Latey is the Head of the Development Operations, Biopharma team within PPD, part of Thermo Fisher Scientific. He has been involved in clinical research and trial management since 1999. Matt has held various, increased levels of leadership responsibility in project management and development operations within PPD. Today, as the Head of Development Operations, Matt leads a group of 30 professionals who are single points of operations and relationship accountability across biopharma accounts. His team specializes in strategic planning and portfolio oversight, spanning across all trial phases, TAs, functional areas and business units. Additionally, Development Operations advance solutions to improve delivery performance, accelerate clinical development and champion patient access, in collaboration with PPD and client stakeholders and subject material experts.
Message Presenter
April de Lima, Executive Director, Strategic Business Solutions, PPD, Part of Thermo Fisher Scientific
April de Lima is an executive director within the Strategic Business Solutions division of PPD, part of Thermo Fisher Scientific. She joined PPD in 2013 and has held roles of increasing responsibility leading teams in talent acquisition and development. In 2022, April was selected to bring to fruition and lead PPD’s Clinical Development Academy, a scalable, innovative, and fit-for-purpose program to attract, select, onboard, and train early and mid-career professionals to build strong clinical development talent pipelines.
April has bachelor’s degrees in biology and psychology with a minor in chemistry from the University of North Carolina at Chapel Hill.
Message Presenter
Anuj Kapadia, VP, Strategy and Corporate Development, PPD, part of Thermo Fisher Scientific
Anuj Kapadia is a Vice President of PPD’s Strategy and Corporate Development team. In his role, Anuj collaborates with senior leadership on key strategy and M&A initiatives, as well as leads the enterprise strategic planning and competitive intelligence functions. He plays a key role in driving PPD’s evolution, growth and differentiation within the broader CRO industry. He also identifies innovator companies (mainly data/tech) and manages strategic partnerships for the company.
Anuj joined PPD in March 2021. Prior to this, he was a ‘career consultant’ with 12+ years of global experience across the broader life sciences and healthcare industries. His consulting experience includes working with pharma, med device and biotech executives to develop and execute their organic and inorganic growth plans.
Anuj has a bachelor’s degree in accounting and economics from the University of Mumbai and an MBA from the Indian School of Business.
Message PresenterWho Should Attend?
This webinar will appeal to the executives and business service team members at biotech and biopharma companies and leaders in:
- Clinical development
- Operations
- Peri-/post-approval
- Quality and regulatory
- Preclinical development
- Business services
- Commercial/marketing
What You Will Learn
Attendees will gain insights into:
- Industry trends, innovations, challenges and sentiments leading the way in 2023, and how to prepare for 2024
- Differences shaping the industry by geography
- How biotech and biopharma companies are approaching key issues differently
Xtalks Partner
PPD
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, its capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, PPD clinical research serves pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, the business applies cutting-edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.
Related Webinars
Leveraging AI for Clinical Trial Efficiencies
The Impact of GLP-1s on Cardiovascular Clinical Development
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account